GLI1 and cancer: As a result, inhibitors of the Shh–GLI1 pathway, such as cyclopamine, have been effectively tested in several cancer types, including medulloblastoma, small-cell lung cancer (SCLC), pancreatic adenocarcinoma, gastric adenocarcinomas, and esophageal cancer [111,112].